Counterpart Health appoints Blaine Lindsey and Shannon Jacobs to enhance partnerships and operations for its AI-driven physician platform.
Quiver AI Summary
Counterpart Health, Inc., a subsidiary of Clover Health Investments, has announced the appointment of Blaine Lindsey and Shannon Jacobs to key leadership positions as part of its strategy to enhance partnerships and operational support for its AI-driven platform, Counterpart Assistant (CA). These hires come at a critical time as many physicians, especially in underserved areas, struggle with the infrastructure needed for implementing value-based care. Counterpart Assistant aims to bridge this gap by integrating AI insights into clinicians' workflows to better manage high-risk patients and support value-based care. Lindsey will focus on expanding partnerships with risk-bearing organizations, leveraging his extensive experience in value-based care, while Jacobs will oversee the growth of Counterpart’s physician network in the Gulf Region, applying his operational expertise to improve care delivery. The technology behind Counterpart Assistant has been demonstrated to improve healthcare outcomes and reduce costs nationwide.
Potential Positives
- Counterpart Health has appointed two experienced leaders, Blaine Lindsey and Shannon Jacobs, to key strategic positions, which strengthens its leadership team and enhances its ability to form valuable partnerships and optimize operations.
- The launch of Counterpart Assistant (CA) addresses the significant technology gap faced by physicians in underserved areas, aiming to improve care delivery through AI-powered insights that fit seamlessly into existing workflows.
- Counterpart Assistant has demonstrated real-world effectiveness in enhancing clinical outcomes, evidenced by published studies, which may attract more healthcare organizations to adopt the technology.
- Blaine Lindsey's expertise in building high-performance partnerships and Shannon Jacobs’ experience in expanding services in diverse markets position Counterpart Health for significant growth and impact in the healthcare sector.
Potential Negatives
- Appointment of leadership comes during a period of significant challenges in technology adoption for value-based care, potentially indicating issues with the existing operational support and infrastructure.
- The press release does not provide specific metrics or results to support claims of success with Counterpart Assistant, which may raise questions about the effectiveness and reliability of the platform.
- There is a notable emphasis on the need for operational support and technology in underserved areas, suggesting that existing solutions may not be adequately meeting the needs of these markets, reflecting a potential gap in service.
FAQ
Who are the new leadership appointments at Counterpart Health?
Blaine Lindsey and Shannon Jacobs have joined Counterpart Health in strategic leadership roles.
What is Counterpart Assistant (CA)?
Counterpart Assistant is an AI-powered platform that helps clinicians manage chronic conditions and deliver value-based care.
How does CA support clinicians in underserved areas?
CA provides actionable intelligence, helping clinicians identify high-risk patients and manage conditions even with limited resources.
What experience do Blaine Lindsey and Shannon Jacobs bring?
Blaine Lindsey has expertise in enterprise partnerships, while Shannon Jacobs has deep operational experience in value-based care.
What is the goal of Counterpart Health?
Counterpart Health aims to improve patient outcomes and reduce healthcare costs through innovative technology in clinical practice.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CLOV Insider Trading Activity
$CLOV insiders have traded $CLOV stock on the open market 11 times in the past 6 months. Of those trades, 4 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $CLOV stock by insiders over the last 6 months:
- VIVEK GARIPALLI has made 2 purchases buying 446,980 shares for an estimated $998,996 and 0 sales.
- CONRAD WAI (CEO, Counterpart Health) has made 0 purchases and 2 sales selling 209,797 shares for an estimated $692,968.
- JAMIE L. REYNOSO (CEO, Medicare Advantage) has made 0 purchases and 5 sales selling 53,988 shares for an estimated $150,179.
- ANNA U LOENGARD has made 2 purchases buying 26,500 shares for an estimated $68,755 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CLOV Hedge Fund Activity
We have seen 117 institutional investors add shares of $CLOV stock to their portfolio, and 88 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 20,029,317 shares (+193.2%) to their portfolio in Q2 2025, for an estimated $55,881,794
- GEODE CAPITAL MANAGEMENT, LLC added 4,812,368 shares (+95.7%) to their portfolio in Q2 2025, for an estimated $13,426,506
- MILLENNIUM MANAGEMENT LLC removed 4,745,791 shares (-81.8%) from their portfolio in Q2 2025, for an estimated $13,240,756
- STATE STREET CORP added 4,580,664 shares (+156.5%) to their portfolio in Q2 2025, for an estimated $12,780,052
- VANGUARD GROUP INC added 3,665,917 shares (+17.8%) to their portfolio in Q2 2025, for an estimated $10,227,908
- BANK OF AMERICA CORP /DE/ added 2,748,783 shares (+217.5%) to their portfolio in Q2 2025, for an estimated $7,669,104
- NORTHERN TRUST CORP added 2,341,788 shares (+226.4%) to their portfolio in Q2 2025, for an estimated $6,533,588
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CLOV Analyst Ratings
Wall Street analysts have issued reports on $CLOV in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 08/07/2025
To track analyst ratings and price targets for $CLOV, check out Quiver Quantitative's $CLOV forecast page.
$CLOV Price Targets
Multiple analysts have issued price targets for $CLOV recently. We have seen 2 analysts offer price targets for $CLOV in the last 6 months, with a median target of $3.55.
Here are some recent targets:
- Richard Close from Canaccord Genuity set a target price of $4.1 on 08/07/2025
- Jonathan Yong from UBS set a target price of $3.0 on 08/06/2025
Full Release
SAN FRANCISCO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) and a leading AI‑powered physician‑enablement platform, today announced that Blaine Lindsey, Vice President of Enterprise Growth and Partnerships and Shannon Jacobs, President of Market Operations for the Gulf Region have joined Counterpart Health. These two strategic leadership appointments are integral to nurturing new partnerships and ensuring operational support for successful adoption of Counterpart Assistant (CA).
These appointments come during a time when many physicians lack the technology infrastructure and operational support to successfully implement value-based care, especially in underserved areas where clinicians may have limited resources. CA addresses this gap by surfacing AI-powered insights into existing clinician workflows, enabling them to identify high-risk patients, manage chronic conditions earlier, and support value-based care at scale.
"Counterpart Assistant was built to serve the full spectrum of physician practices," said Conrad Wai, CEO of Counterpart Health. "Whether we're partnering with large health systems, national plans, regional payviders, or independent practices in rural communities, we’ve identified that the need is the same: actionable intelligence that improves care without overwhelming providers. Blaine and Shannon bring the expertise to scale our impact while ensuring we deliver meaningful results.”
Driving National Enterprise Partnerships
As Vice President of Enterprise Growth and Partnerships, Blaine Lindsey will be instrumental in bringing Counterpart Assistant to more risk-bearing organizations, and ultimately, more clinicians and patients. Lindsey is a highly accomplished healthcare leader and nationally recognized value-based care expert whose experience includes leading national provider and enterprise partnerships at Aledade and Honest Health as well as driving expansion as Chief Growth Officer at AnsibleHealth. Lindsey brings a proven track record of building innovative, high performance partnerships that deliver both clinical and financial value.
“Counterpart’s technology has proven itself in real-world deployments and consistently outperforms in actual practice settings,” said Blaine Lindsey. “The healthcare ecosystem is taking notice of Counterpart Assistant with new partners requesting access, and inbound demand is building quickly. My priority is to convert that momentum into strategic partnerships that deliver reliable, measurable results for clinicians while scaling adoption within existing workflows.”
Scaling Operations in the Gulf Region's Diverse Markets
Shannon Jacobs joins as President of Market Operations for the Gulf Region, where he'll lead the expansion and performance optimization of Counterpart’s growing physician network. Jacobs most recently served as President of the Gulf Region at Main Street Health, the nation's largest value-based care provider in rural communities. He brings deep operational expertise in launching new markets, building high-performing teams, and supporting excellent clinical care delivery across diverse practice environments.
"I've worked closely with primary care providers for years and have tremendous respect for how they navigate a myriad of challenges, especially in areas where resources are tight and patient complexity is high,” said Shannon Jacobs. “What excites me about Counterpart Assistant is the opportunity to support these hard-working providers with valuable clinical data and AI-enabled technology that fits into their existing workflows and allows them to deliver high quality care to their patients.”
About Counterpart Health
Counterpart Health
, a subsidiary of Clover Health Investments, Corp., or Clover Health, is a leading AI-powered physician enablement platform transforming care delivery. Born out of Clover Health as Clover Assistant, Counterpart Health’s flagship software platform, Counterpart Assistant, provides clinically intuitive insights that help clinicians better manage chronic conditions and deliver high-quality care. Counterpart Health extends this powerful data-driven technology platform beyond Clover Health’s Medicare Advantage plan, bringing its benefits to a wider audience to improve patient outcomes and reduce healthcare costs nationwide. Several published studies demonstrate the technology’s impact on
Diabetes
,
Chronic Kidney Disease
,
Congestive Heart Failure
, and
Chronic Obstructive Pulmonary Disease
management, and
Clinical Quality
.
Investor Relations:
Ryan Schmidt
[email protected]
Press Inquiries:
[email protected]